ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

November 22, 2022

Study Completion Date

December 13, 2022

Conditions
Food Allergy
Interventions
BIOLOGICAL

Low dose ADP101

Active powder formulation

BIOLOGICAL

High dose ADP101

Active powder formulation.

BIOLOGICAL

Pooled Placebo

Placebo powder

Trial Locations (15)

19104

Study Site, Philadelphia

27599

Study Site, Chapel Hill

29420

Study Site, Charleston

30060

Study Site, Marietta

30329

Study Site, Atlanta

33620

Study Site, Tampa

45229

Study Site, Cincinnati

48108

Study Site, Ann Arbor

61761

Study Site, Normal

80230

Study Site, Denver

90274

Study Site, Rolling Hills Estates

92123

Study Site, San Diego

92691

Study Site, Mission Viejo

97086

Study Site, Happy Valley

98115

Study Site, Seattle

All Listed Sponsors
lead

Alladapt Immunotherapeutics, Inc.

INDUSTRY

NCT04856865 - ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults | Biotech Hunter | Biotech Hunter